Blueprint Medicines Corporation Financial Statements (BPMC)
|
|
|
|
Report date
|
|
|
13.02.2020 |
17.02.2021 |
17.02.2022 |
16.02.2023 |
15.02.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
66.5 |
793.7 |
180.1 |
204.0 |
249.4 |
|
434.4 |
|
Operating Income, bln rub |
|
|
-366.6 |
302.1 |
-648.5 |
-549.3 |
-486.3 |
|
-276.0 |
|
EBITDA, bln rub |
? |
|
-356.1 |
308.7 |
-628.3 |
-515.4 |
-474.6 |
|
-240.4 |
|
Net profit, bln rub |
? |
|
-328.7 |
313.9 |
-644.1 |
-557.5 |
-507.0 |
|
-128.1 |
|
|
OCF, bln rub |
? |
|
-278.0 |
387.0 |
-298.7 |
-502.3 |
-436.8 |
|
-242.2 |
|
CAPEX, bln rub |
? |
|
14.0 |
3.16 |
261.2 |
8.92 |
16.1 |
|
8.37 |
|
FCF, bln rub |
? |
|
-292.0 |
383.9 |
-559.9 |
-511.2 |
-452.9 |
|
-250.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
427.8 |
484.6 |
804.1 |
723.7 |
722.9 |
|
687.4 |
|
Cost of production, bln rub |
|
|
0.000 |
0.425 |
17.9 |
17.8 |
12.8 |
|
22.9 |
|
R&D, bln rub |
|
|
331.5 |
326.9 |
601.0 |
477.4 |
427.7 |
|
345.3 |
|
Interest expenses, bln rub |
|
|
13.7 |
0.000 |
0.000 |
16.8 |
0.000 |
|
65.6 |
|
|
Assets, bln rub |
|
|
707.7 |
1 718 |
1 252 |
1 350 |
1 049 |
|
1 200 |
|
Net Assets, bln rub |
? |
|
464.4 |
1 470 |
970.7 |
514.7 |
130.6 |
|
313.1 |
|
Debt, bln rub |
|
|
95.9 |
89.6 |
111.4 |
242.5 |
774.1 |
|
471.5 |
|
Cash, bln rub |
|
|
548.0 |
1 550 |
1 035 |
1 078 |
710.6 |
|
734.2 |
|
Net debt, bln rub |
|
|
-452.0 |
-1 460 |
-923.2 |
-836.0 |
63.5 |
|
-262.7 |
|
|
Ordinary share price, rub |
|
|
80.1 |
112.2 |
107.1 |
43.8 |
92.2 |
|
59.5 |
|
Number of ordinary shares, mln |
|
|
47.8 |
54.5 |
58.5 |
59.6 |
60.6 |
|
63.4 |
|
|
Market cap, bln rub |
|
|
3 832 |
6 116 |
6 268 |
2 613 |
5 586 |
|
3 769 |
|
EV, bln rub |
? |
|
3 380 |
4 656 |
5 345 |
1 777 |
5 649 |
|
3 506 |
|
Book value, bln rub |
|
|
464 |
1 470 |
971 |
515 |
131 |
|
313 |
|
|
EPS, rub |
? |
|
-6.87 |
5.76 |
-11.0 |
-9.35 |
-8.37 |
|
-2.02 |
|
FCF/share, rub |
|
|
-6.11 |
7.04 |
-9.57 |
-8.57 |
-7.48 |
|
-3.95 |
|
BV/share, rub |
|
|
9.71 |
27.0 |
16.6 |
8.63 |
2.16 |
|
4.94 |
|
|
EBITDA margin, % |
? |
|
-535.3% |
38.9% |
-348.9% |
-252.6% |
-190.3% |
|
-55.3% |
|
Net margin, % |
? |
|
-494.2% |
39.5% |
-357.7% |
-273.2% |
-203.3% |
|
-29.5% |
|
FCF yield, % |
? |
|
-7.62% |
6.28% |
-8.93% |
-19.6% |
-8.11% |
|
-6.65% |
|
ROE, % |
? |
|
-70.8% |
21.4% |
-66.4% |
-108.3% |
-388.2% |
|
-40.9% |
|
ROA, % |
? |
|
-46.4% |
18.3% |
-51.4% |
-41.3% |
-48.3% |
|
-10.7% |
|
|
P/E |
? |
|
-11.7 |
19.5 |
-9.73 |
-4.69 |
-11.0 |
|
-29.4 |
|
P/FCF |
|
|
-13.1 |
15.9 |
-11.2 |
-5.11 |
-12.3 |
|
-15.0 |
|
P/S |
? |
|
57.6 |
7.71 |
34.8 |
12.8 |
22.4 |
|
8.68 |
|
P/BV |
? |
|
8.25 |
4.16 |
6.46 |
5.08 |
42.8 |
|
12.0 |
|
EV/EBITDA |
? |
|
-9.49 |
15.1 |
-8.51 |
-3.45 |
-11.9 |
|
-14.6 |
|
Debt/EBITDA |
|
|
1.27 |
-4.73 |
1.47 |
1.62 |
-0.13 |
|
1.09 |
|
|
R&D/CAPEX, % |
|
|
2 365% |
10 347% |
230.1% |
5 353% |
2 663% |
|
4 125% |
|
|
CAPEX/Revenue, % |
|
|
21.1% |
0.40% |
145.1% |
4.37% |
6.44% |
|
1.93% |
|
| Blueprint Medicines Corporation shareholders |
